Literature DB >> 8150066

Risk factors for severe disease due to Toxoplasma gondii in HIV-positive patients.

H J Stellbrink1, R Führer-Burow, A Raedler, H Albrecht, S Fenske.   

Abstract

The objective of this study was to assess the risk of toxoplasmosis in HIV-positive subjects as a basis for primary prophylaxis. A retrospective chart review of 400 consecutive patients was carried out and clinical and laboratory markers at first presentation and follow-up data on the occurrence of toxoplasmosis were recorded. Independent variables were identified, laboratory parameters were stratified, and estimates for the risk of toxoplasmosis and the impact of different variables on its occurrence were made using conventional statistical methods. An increased risk of toxoplasmosis was strongly associated with a positive Toxoplasma gondii IgG EIA in conjunction with a CD4+ cell cont below 0.15/nl (the estimated risk of toxoplasmosis was 20% and 35% after 12 and 24 months, respectively) or a history of one or more opportunistic infections (the estimated risk was 12% and 30% after 12 and 24 months, respectively). Toxoplasma gondii-seropositive patients with CD4+ cell counts below 0.15/nl and those with antecedent opportunistic infections are most likely to develop toxoplasmosis and thus might benefit from primary prophylaxis. The risk of disease probably outweighs the risk of medication in these subjects. Prospective clinical trials are needed to define the optimal choice of drugs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8150066     DOI: 10.1007/bf00211438

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  10 in total

1.  Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis.

Authors:  B Clotet; G Sirera; J Romeu; J M Gimeno; A Jou; M J Condom; J Tor; M Foz
Journal:  AIDS       Date:  1991-05       Impact factor: 4.177

Review 2.  Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature.

Authors:  R M Levy; D E Bredesen; M L Rosenblum
Journal:  J Neurosurg       Date:  1985-04       Impact factor: 5.115

3.  Toxoplasma encephalitis in patients with acquired immune deficiency syndrome: diagnosis and response to therapy.

Authors:  C Wanke; C U Tuazon; A Kovacs; T Dina; D O Davis; N Barton; D Katz; M Lunde; C Levy; F K Conley
Journal:  Am J Trop Med Hyg       Date:  1987-05       Impact factor: 2.345

4.  Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS.

Authors:  I H Grant; J W Gold; M Rosenblum; D Niedzwiecki; D Armstrong
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

5.  Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS.

Authors:  A Carr; B Tindall; B J Brew; D J Marriott; J L Harkness; R Penny; D A Cooper
Journal:  Ann Intern Med       Date:  1992-07-15       Impact factor: 25.391

Review 6.  Toxoplasmic encephalitis in AIDS.

Authors:  B J Luft; J S Remington
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

7.  Central nervous system toxoplasmosis in homosexual men.

Authors:  K P Anderson; E Atlas; M J Ahern; I M Weisbrot
Journal:  Am J Med       Date:  1983-11       Impact factor: 4.965

8.  High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii.

Authors:  R Zangerle; F Allerberger; P Pohl; P Fritsch; M P Dierich
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

9.  Central-nervous-system toxoplasmosis in homosexual men and parenteral drug abusers.

Authors:  B Wong; J W Gold; A E Brown; M Lange; R Fried; M Grieco; D Mildvan; J Giron; M L Tapper; C W Lerner
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

10.  Murine model of intracerebral toxoplasmosis.

Authors:  J M Hofflin; F K Conley; J S Remington
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

  10 in total
  1 in total

1.  Toxoplasma gondii surface antigen-1 in sera of HIV-infected patients as an indicator of reactivated toxoplasmosis.

Authors:  M F Letillois; V Laigle; F Santoro; M Micoud; B F Chumpitazi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-10       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.